Description of the clinical characteristics of the patients included in the study according to the adherence to treatment (according to Morisky-Green test)
| Variable | Total | Non-adherent | Adherent | p Value |
|---|---|---|---|---|
| Number of medicines/patient* (median/IQR) (minimum 0 to maximum 12) | 4 (2–6) | <0.001 | ||
| ≤5 | 414 | 151 (36.5%) | 263 (63.5%) | |
| >5 | 188 | 41 (21.8%) | 147 (78.2%) | |
| Have you ever suffered a cardiovascular event? | 0.734 | |||
| No | 488 | 159 (32.6%) | 329 (67.4%) | |
| Yes | 108 | 31 (28.7%) | 77 (71.3%) | |
| Unknown | 6 | 2 (33.3%) | 4 (66.7%) | |
| When? | 0.540 | |||
| 0–5 years | 41 | 11 (26.8%) | 30 (73.2%) | |
| 6–10 years | 21 | 5 (23.8%) | 16 (76.2%) | |
| 11–15 years | 10 | 4 (40.0%) | 6 (60.0%) | |
| >15 years | 8 | 1 (12.5%) | 7 (87.5%) | |
| Unknown | 28 | 11 (37.9%) | 18 (82.1%) | |
| Number of diseases/patient* (median/IQR) (minimum 0 to maximum 8) | 2 (1–3) | 2 (1–2) | 2 (1–3) | 0.057 |
| Active principle | 0.427 | |||
| Valsartan | 126 | 36 (28.6%) | 90 (71.4%) | |
| Valsartan/hydrochlorothiazide | 135 | 39 (28.9%) | 96 (71.1%) | |
| Telmisartan | 71 | 30 (42.3%) | 41 (57.7%) | |
| Telmisartan/hydrochlorothiazide | 59 | 20 (33.9%) | 39 (66.1%) | |
| Candesartan | 68 | 22 (32.4%) | 46 (67.6%) | |
| Candesartan/hydrochlorothiazide | 48 | 16 (33.3%) | 32 (66.7%) | |
| Irbesartan | 50 | 17 (34.0%) | 33 (66.0%) | |
| Irbesartan/hydrochlorothiazide | 45 | 1 (100.0%) | 0 | |
| What is the medication indicated for? | 0.537 | |||
| Hypertension | 565 | 183 (32.4%) | 382 (67.6%) | |
| Other answer | 10 | 3 (30.0%) | 7 (70.0%) | |
| Unknown | 27 | 6 (22.2%) | 21 (77.8%) | |
| How long have you been following this treatment? | 0.002 | |||
| ≤6 months | 26 | 2 (7.7%) | 24 (92.3%) | |
| >6 months to 1 year | 27 | 15 (55.6%) | 12 (44.4%) | |
| >1 year | 548 | 174 (31.8%) | 374 (68.2%) | |
| Unknown | 1 | 1 (100.0) | 0 | |
| How do you keep this medicine at home? | 0.815 | |||
| In its package | 471 | 153 (32.5%) | 318 (67.5%) | |
| In a pillbox | 74 | 20 (27.0%) | 54 (73.0%) | |
| In its blister | 57 | 19 (27.1%) | 38 (66.7%) |
*We did not include either the medicine under study or the disease under study.